Jayasekera J, et al. - Researchers assessed 1,778 females to estimate the impacts of radiotherapy after lumpectomy in women with early-stage, low-recurrence risk, hormone-sensitive breast cancer by using gene expression profiling (GEP) information with pooled individual-level data. Five-year recurrence-free interval (RFI) rate was noted high (93.5%) for no radiotherapy and 97.9% for radiotherapy. They recorded variations in the results of radiotherapy across subgroups, with lower RFI rates for those with Oncotype scores of less than 11 (vs 11–18), older (vs younger), and ER+/PR+ status (vs other). They observed a statistically significant increment in any first locoregional recurrence, but not distant recurrence events, or breast cancer-specific or overall survival.